BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 16137213)

  • 21. Impact of a clinical pharmacy program on changes in hemoglobin A1c, diabetes-related hospitalizations, and diabetes-related emergency department visits for patients with diabetes in an underserved population.
    Chung N; Rascati K; Lopez D; Jokerst J; Garza A
    J Manag Care Spec Pharm; 2014 Sep; 20(9):914-9. PubMed ID: 25166290
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Impact of Reducing Glycated Hemoglobin on Healthcare Costs Among a Population with Uncontrolled Diabetes.
    Bansal M; Shah M; Reilly B; Willman S; Gill M; Kaufman FR
    Appl Health Econ Health Policy; 2018 Oct; 16(5):675-684. PubMed ID: 29936685
    [TBL] [Abstract][Full Text] [Related]  

  • 23. DOES CLINICAL INERTIA VARY BY PERSONALIZED A1C GOAL? A STUDY OF PREDICTORS AND PREVALENCE OF CLINICAL INERTIA IN A U.S. MANAGED-CARE SETTING.
    Lin J; Zhou S; Wei W; Pan C; Lingohr-Smith M; Levin P
    Endocr Pract; 2016 Feb; 22(2):151-61. PubMed ID: 26492540
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Administrative claims analysis of utilization and costs of care in health plan members with atopic dermatitis who had prior use of a topical corticosteroid and who initiate therapy with pimecrolimus or tacrolimus.
    Delea TE; Gokhale M; Makin C; Hussein MA; Vanderpoel J; Sandman T; Chang J; Sung J; Pinkston P; Gause D; Jackson M
    J Manag Care Pharm; 2007 May; 13(4):349-59. PubMed ID: 17506601
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effect of Weight Change on Economic Outcomes Among Persons with Type 2 Diabetes Mellitus in the United States: Beyond Glycemic Control.
    Karkare S; Fridman M; Dang-Tan T; Lu J; Smolarz BG; DeKoven M; Iyer NN
    J Manag Care Spec Pharm; 2019 Jun; 25(6):658-668. PubMed ID: 30730232
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Impact of medication adherence and persistence on clinical and economic outcomes in patients with type 2 diabetes treated with liraglutide: a retrospective cohort study.
    Buysman EK; Liu F; Hammer M; Langer J
    Adv Ther; 2015 Apr; 32(4):341-55. PubMed ID: 25832470
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Cost of self-monitoring of blood glucose in the United States among patients on an insulin regimen for diabetes.
    Yeaw J; Lee WC; Aagren M; Christensen T
    J Manag Care Pharm; 2012; 18(1):21-32. PubMed ID: 22235952
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Predictors of glycemic control and diabetes-related costs among type 2 diabetes patients initiating therapy with liraglutide in the United States.
    Durden E; Lenhart G; Lopez-Gonzalez L; Hammer M; Langer J
    J Med Econ; 2016; 19(4):403-13. PubMed ID: 26653068
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Short-term economic impact of body weight change among patients with type 2 diabetes treated with antidiabetic agents: analysis using claims, laboratory, and medical record data.
    Yu AP; Wu EQ; Birnbaum HG; Emani S; Fay M; Pohl G; Wintle M; Yang E; Oglesby A
    Curr Med Res Opin; 2007 Sep; 23(9):2157-69. PubMed ID: 17669232
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effect of Diabetes Treatment-Related Attributes on Costs to Type 2 Diabetes Patients in a Real-World Population.
    Meng J; Casciano R; Lee YC; Stern L; Gultyaev D; Tong L; Kitio-Dschassi B
    J Manag Care Spec Pharm; 2017 Apr; 23(4):446-452. PubMed ID: 28345434
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Analysis of Glycemic Control of a Pharmacist-Led Medication Management Program in Patients with Type 2 Diabetes.
    Ko JJ; Lu J; Rascati K; Stock EM; Juan J; Suh K; Kim Y; Tabor PA; Godley PJ
    J Manag Care Spec Pharm; 2016 Jan; 22(1):32-7. PubMed ID: 27015049
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Descriptive analysis of the direct medical costs of multiple sclerosis in 2004 using administrative claims in a large nationwide database.
    Prescott JD; Factor S; Pill M; Levi GW
    J Manag Care Pharm; 2007; 13(1):44-52. PubMed ID: 17269836
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Association Between Weight Change, Clinical Outcomes, and Health Care Costs in Patients with Type 2 Diabetes.
    Mukherjee J; Sternhufvud C; Smith N; Bell K; Stott-Miller M; McMorrow D; Johnston S
    J Manag Care Spec Pharm; 2016 May; 22(5):449-66. PubMed ID: 27123909
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Humanistic, utilization, and cost outcomes associated with the use of botulinum toxin for treatment of refractory migraine headaches in a managed care organization.
    Mitchell MP; Schaecher K; Cannon HE; Speckman M
    J Manag Care Pharm; 2008 Jun; 14(5):442-50. PubMed ID: 18597573
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Repaglinide : a pharmacoeconomic review of its use in type 2 diabetes mellitus.
    Plosker GL; Figgitt DP
    Pharmacoeconomics; 2004; 22(6):389-411. PubMed ID: 15099124
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Secondary failure of glycemic control for patients adding thiazolidinedione or sulfonylurea therapy to a metformin regimen.
    Riedel AA; Heien H; Wogen J; Plauschinat CA
    Am J Manag Care; 2007 Aug; 13(8):457-63. PubMed ID: 17685826
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Evaluation of a Pharmacist-Managed Diabetes Program in a Primary Care Setting Within an Integrated Health Care System.
    Benedict AW; Spence MM; Sie JL; Chin HA; Ngo CD; Salmingo JF; Vidaurreta AT; Rashid N
    J Manag Care Spec Pharm; 2018 Feb; 24(2):114-122. PubMed ID: 29384029
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Lowering Cost Share May Improve Rates of Home Glucose Monitoring Among Patients with Diabetes Using Insulin.
    Xie Y; Agiro A; Bowman K; DeVries A
    J Manag Care Spec Pharm; 2017 Aug; 23(8):884-891. PubMed ID: 28737991
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Clinical and Economic Outcomes of Patients with Type 2 Diabetes on Multiple Daily Injections of Basal-bolus Insulin (MDI) Therapy: A Retrospective Cohort Study.
    Brixner D; Ermakova A; Xiong Y; Sieradzan R; Sacks N; Cyr P; Taylor SD
    Clin Ther; 2019 Feb; 41(2):303-313.e1. PubMed ID: 30709610
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Evaluation of the relationship between a chronic disease care management program and california pay-for-performance diabetes care cholesterol measures in one medical group.
    Cutler TW; Palmieri J; Khalsa M; Stebbins M
    J Manag Care Pharm; 2007 Sep; 13(7):578-88. PubMed ID: 17874864
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.